## FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

ECU	KH	IE2	AND	EXCHANGE	COMMISSION

OMB API	PROVAL
OMB Number:	3235-0287
Estimated average	burden

0.5

hours per response:

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*  Levy Richard S				2. Issuer Name and Ticker or Trading Symbol Kiniksa Pharmaceuticals International, plc KNSA ]							[ (Che	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director  Officer (give title  Other (specify)			vner			
(Last) (First) (Middle)					3. Date of Earliest Transaction (Month/Day/Year)								below)	(give title		below)	эреспу	
23 OLD BOND STREET, THIRD FLOOR						11/07/2024												
(Street) LONDO (City)			W1S 4PZ (Zip)		4. If Amendment, Date of Original Filed (Month/Day/Year)						Line	Individual or Joint/Group Filing (Check Applicable ne)  Form filed by One Reporting Person  Form filed by More than One Reporting Person						
			ole I - Non			_				Dis		-		_				
D D				2. Transaction Date (Month/Day/Year)		Ex r) if a	2A. Deemed Execution Date, if any (Month/Day/Year)		3. 4. Securities Acc Transaction Disposed Of (D) Code (Instr. 5)				5. Amour Securitie Beneficia Owned F	s ally ollowing	Form:	Direct Indirect str. 4)	7. Nature of Indirect Beneficial Ownership	
								Code	v	Amount	(A) or (D)	Price	Transact	Reported Transaction(s) (Instr. 3 and 4)			(Instr. 4)	
Class A Ordinary Share 11/0					7/2024		М		1,303	03 A		14,	1,200		D			
		-	Table II - D								osed of, onvertib			Owned				
1. Title of Derivative Security (Instr. 3)	Derivative Conversion Date Security or Exercise (Month/Day/Year) if a		3A. Deemed Execution Da if any (Month/Day/	ate, Tr	ransaction   Deriva   Securi   Acquir   or Dis   of (D)		Derivative E		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
				Co	ode V		(A)	(D)	Date Exercisa		Expiration Date	Title	Amount or Number of Shares		Transaction(s (Instr. 4)			
Restricted Share Units	(1)	11/07/2024			A		1,303		(2)		(2)	Class A Ordinary Shares	1,303	\$0	1,303		D	
Restricted Share Units	(1)	11/07/2024		1	М			1,303	(2)		(2)	Class A Ordinary Shares	1,303	\$0	0		D	

## Explanation of Responses:

- 1. Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.
- 2. The RSUs vested immediately upon grant on November 7, 2024; there was no expiration date for the RSUs.

/s/ Madelyn Zeylikman, Attorney-in-Fact

11/12/2024

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.